Skip to content

Venture

LOGO 8-01

Affiliations

SUNY

Technologies

Therapeutic

Indication

Basic Research

Drug Discovery

Molecular Diagnostic

Oncology

Orphan Diseases

Personalized Medicine

Utilizing a novel immunologic approach, NomoCan Pharmaceuticals is developing a targeted therapy for the treatment and prognosis of the most aggressive human cancer, pancreatic cancer.

NomoCan Pharmaceuticals Team:

Ehsan Sarafraz-Yazdi, PhD

Kamyar Neshvadian, FRM